Waters Corporation (WAT)
| Market Cap | 42.88B +119.4% |
| Revenue (ttm) | 4.64B +52.5% |
| Net Income | 166.63M -74.8% |
| EPS | 2.21 -80.0% |
| Shares Out | 98.25M |
| PE Ratio | 197.05 |
| Forward PE | 28.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,074,982 |
| Open | 445.74 |
| Previous Close | 440.12 |
| Day's Range | 431.62 - 454.54 |
| 52-Week Range | 282.77 - 454.54 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | 453.26 (+3.86%) |
| Earnings Date | Nov 3, 2026 |
About WAT
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, p... [Read more]
Financial Performance
In 2025, Waters's revenue was $3.17 billion, an increase of 6.99% compared to the previous year's $2.96 billion. Earnings were $642.63 million, an increase of 0.75%.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for WAT stock is "Buy." The 12-month stock price target is $453.26, which is an increase of 3.86% from the latest price.
News
Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
MILFORD, Mass., Oct. 1, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q3 2026 financial results conference call on Tuesday, November 3, 2026, at 8:00 a.m.
Waters price target raised to $490 from $440 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Waters (WAT) to $490 from $440 and keeps a Buy rating on the shares. The firm adjusted its models and…
Waters Transcript: U.S. All Stars Conference
Revised summary: Strong Q2 growth was driven by robust performance in instruments, chemistry, and emerging markets, with AI and innovation fueling demand, especially in QC. Integration of acquisitions is ahead of schedule, with cost synergies and new product launches. Margin expansion and high single-digit growth are expected, with China and personalized medicine as key drivers.
Waters price target raised to $515 from $465 at Goldman Sachs
Goldman Sachs analyst Evie Koslosky raised the firm’s price target on Waters (WAT) to $515 from $465 and keeps a Buy rating on the shares.
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
AUSTIN, Texas--(BUSINESS WIRE)--Everlywell, a leader in digital health, today announced a partnership with Waters Corporation to ensure patients have access to the most comprehensive at-home HPV cervi...
Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Enables routine 50+ parameter experiments with BD SpectralFX™ Technology, accelerating breakthrough discoveries in the fight against cancer and other diseases. Minimizes instrument and user difference...
Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference
MILFORD, Mass., Sept. 11, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D.
Waters Transcript: Wells Fargo 21st Annual Healthcare Conference
Strong Q2 results were driven by robust growth across instruments, recurring revenue, and chemistry, with China and pharma segments outperforming expectations. Localization, pricing improvements, and integration synergies are fueling momentum, setting up sustained high single-digit growth through 2027.
Waters assumed with a Buy at UBS
UBS analyst Doug Schenkel assumed coverage of Waters (WAT) with a Buy rating and $490 price target The market may still be underappreciating the value creation from Waters’ BD Life…
LetsGetChecked Powered by Fuze Health Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
WEST CHESTER, Ohio--(BUSINESS WIRE)--LetsGetChecked now offers the most comprehensive FDA-cleared at-home HPV screening tool available in the U.S.
Piper upgrades Waters to Overweight on replacement cycle
Piper Sandler upgraded Waters (WAT) to Overweight from Neutral with a price target of $480, up from $400. The firm cites the “strong” replacement cycle and its work in flow…
Waters upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Waters (WAT) to Overweight from Neutral with a price target of $480, up from $400.
Waters Corporation to Present at the Wells Fargo Healthcare Conference
MILFORD, Mass., Aug. 26, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D.
Waters price target raised to $470 from $425 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Waters (WAT) to $470 from $425 and keeps a Buy rating on the shares.
Waters price target raised to $430 from $390 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Waters (WAT) to $430 from $390 and keeps an Equal Weight rating on the shares. Following Q2 earnings and given the latest…
Waters price target raised to $475 from $435 at RBC Capital
RBC Capital raised the firm’s price target on Waters (WAT) to $475 from $435 and keeps an Outperform rating on the shares.
Waters price target raised to $420 from $410 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Waters (WAT) to $420 from $410 and keeps an Outperform rating on the shares.
Waters price target raised to $400 from $380 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Waters (WAT) to $400 from $380 and keeps a Hold rating on the shares.
Waters price target raised to $420 from $380 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Waters (WAT) to $420 from $380 and keeps a Hold rating on the shares.
Waters upgraded to Buy from Hold at TD Cowen
TD Cowen upgraded Waters (WAT) to Buy from Hold with a price target of $475, up from $408, post the Q2 report. The company delivered another solid result in the…
Waters price target raised to $460 from $425 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Waters (WAT) to $460 from $425 and keeps an Overweight rating on the shares post the Q2 report. “So many…
Waters Earnings Call Transcript: Q2 2026
Q2 results exceeded guidance with strong growth across all divisions, especially in pharma, academic/government, and acquired BD businesses. Full-year guidance was raised, with robust margin expansion and cost savings expected. New product launches and strategic partnerships further strengthen growth prospects.
Waters Earnings release: Q2 2026
Waters released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Waters Slides: Q2 2026
Waters has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Waters Quarterly report: Q2 2026
Waters has published its Q2 2026 quarterly earnings report on August 4, 2026.